VFEND® 40 mg/ml powder for oral suspension
voriconazole

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor, pharmacist or nurse.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What VFEND is and what it is used for
2. What you need to know before you take VFEND
3. How to take VFEND
4. Possible side effects
5. How to store VFEND
6. Content of the pack and other information

1. What VFEND is and what it is used for

VFEND contains the active substance voriconazole. VFEND is an antifungal medicine. It works by killing or stopping the growth of the fungi that cause infections.

It is used for the treatment of patients (adults and children over the age of 2) with:

• invasive aspergillosis (a type of fungal infection due to Aspergillus sp),
• candidaemia (another type of fungal infection due to Candida sp) in non-neutropenic patients (patients without abnormally low white blood cells count),
• serious invasive Candida sp. infections when the fungus is resistant to fluconazole (another antifungal medicine),
• serious fungal infections caused by Scedosporium sp. or Fusarium sp. (two different species of fungi).

VFEND is intended for patients with worsening, possibly life-threatening, fungal infections.

Prevention of fungal infections in high risk bone marrow transplant recipients.

This product should only be taken under the supervision of a doctor.

2. What you need to know before you take VFEND

Do not take VFEND
If you are allergic to voriconazole or any of the other ingredients of this medicine (listed in section 6).

It is very important that you inform your doctor or pharmacist if you are taking or have taken any other medicines, even those that are obtained without a prescription, or herbal medicines.

The medicines in the following list must not be taken during your course of VFEND treatment:

• Terfenadine (used for allergy)
• Astemizole (used for allergy)
- Cisapride (used for stomach problems)
- Pimozide (used for treating mental illness)
- Quinidine (used for irregular heart beat)
- Rifampicin (used for treating tuberculosis)
- Efavirenz (used for treating HIV) in doses of 400 mg and above once daily
- Carbamazepine (used to treat seizures)
- Phenobarbital (used for severe insomnia and seizures)
- Ergot alkaloids (e.g., ergotamine, dihydroergotamine; used for migraine)
- Sirolimus (used in transplant patients)
- Ritonavir (used for treating HIV) in doses of 400mg and more twice daily
- St. John’s Wort (herbal supplement)

**Warnings and precautions**
Talk to your doctor, pharmacist or nurse before taking VFEND if:

- you have had an allergic reaction to other azoles.
- you are suffering from, or have ever suffered from liver disease. If you have liver disease, your doctor may prescribe a lower dose of VFEND. Your doctor should also monitor your liver function while you are being treated with VFEND by doing blood tests.
- you are known to have cardiomyopathy, irregular heart beat, slow heart rate or an abnormality of electrocardiogram (ECG) called ‘long QTc syndrome’.

You should avoid any sunlight and sun exposure while being treated. It is important to cover sun exposed areas of skin and use sunscreen with high sun protection factor (SPF), as an increased sensitivity of skin to the sun’s UV rays can occur. These precautions are also applicable to children.

While being treated with VFEND:
- tell your doctor immediately if you develop
  - sunburn
  - severe skin rash or blisters
  - bone pain

If you develop skin disorders as described above, your doctor may refer you to a dermatologist, who after consultation may decide that it is important for you to be seen on a regular basis. There is a small chance that skin cancer could develop with long-term use of VFEND.

If you develop signs of ‘adrenal insufficiency’ where the adrenal glands do not produce adequate amounts of certain steroid hormones such as cortisol which may lead to symptoms such as: chronic, or long lasting fatigue, muscle weakness, loss of appetite, weight loss, abdominal pain, please tell your doctor.

Your doctor should monitor the function of your liver and kidney by doing blood tests.

**Children and adolescents**
VFEND should not be given to children younger than 2 years of age.

**Other medicines and VFEND**
Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including those that are obtained without a prescription.

Some medicines, when taken at the same time as VFEND, may affect the way VFEND works or VFEND may affect the way they work.

Tell your doctor if you are taking the following medicine, as treatment with VFEND at the same time
should be avoided if possible:

- Ritonavir (used for treating HIV) in doses of 100 mg twice daily

Tell your doctor if you are taking either of the following medicines, as treatment with VFEND at the same time should be avoided if possible, and a dose adjustment of voriconazole may be required:

- Rifabutin (used for treating tuberculosis). If you are already being treated with rifabutin your blood counts and side effects to rifabutin will need to be monitored.
- Phenytoin (used to treat epilepsy). If you are already being treated with phenytoin your blood concentration of phenytoin will need to be monitored during your treatment with VFEND and your dose may be adjusted.

Tell your doctor if you are taking any of the following medicines, as a dose adjustment or monitoring may be required to check that the medicines and/ or VFEND are still having the desired effect:

- Warfarin and other anticoagulants (e.g., phenprocoumon, acenocoumarol; used to slow down clotting of the blood)
- Ciclosporin (used in transplant patients)
- Tacrolimus (used in transplant patients)
- Sulfonylureas (e.g., tolbutamide, glipizide, and glyburide) (used for diabetes)
- Statins (e.g., atorvastatin, simvastatin) (used for lowering cholesterol)
- Benzodiazepines (e.g midazolam, triazolam) (used for severe insomnia and stress)
- Omeprazole (used for treating ulcers)
- Oral contraceptives (if you take VFEND whilst using oral contraceptives, you may get side effects such as nausea and menstrual disorders)
- Vinca alkaloids (e.g., vincristine and vinblastine) (used in treating cancer)
- Indinavir and other HIV protease inhibitors (used for treating HIV)
- Non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz, delavirdine, nevirapine) (used for treating HIV) (some doses of efavirenz can NOT be taken at the same time as VFEND)
- Methadone (used to treat heroin addiction)
- Alfentanil and fentanyl and other short-acting opiates such as sufentanil (painkillers used for surgical procedures)
- Oxycodone and other long-acting opiates such as hydrocodone (used for moderate to severe pain)
- Non-steroidal anti-inflammatory drugs (e.g., ibuprofen, diclofenac) (used for treating pain and inflammation)
- Fluconazole (used for fungal infections)
- Everolimus (used for treating advanced kidney cancer and in transplant patients)
- Tolvaptan (used to treat hyponatremia (low levels of sodium in your blood) or to slow kidney function decline in patients with polycystic kidney disease)
- Letermovir (used for preventing cytomegalovirus (CMV) disease after bone marrow transplant)
- Naloxegol: used to treat constipation specifically caused by pain medicines, called opioids, (e.g., morphine, oxycodone, fentanyl, tramadol, codeine)
- Ivacaftor: used to treat cystic fibrosis

**Pregnancy and breast-feeding**
VFEND must not be taken during pregnancy, unless indicated by your doctor. Effective contraception must be used in women of childbearing potential. Contact your doctor immediately if you become pregnant while taking VFEND.

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
VFEND may cause blurring of vision or uncomfortable sensitivity to light. While affected, do not drive or operate any tools or machines. Contact your doctor if you experience this.

VFEND contains sucrose
This medicine contains 0.54g sucrose per ml of suspension. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking VFEND. This should be taken into account in patients with diabetes mellitus. May be harmful to the teeth.

VFEND contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per 5 ml of suspension, that is to say essentially ‘sodium-free’.

VFEND contains benzoate salt/sodium
This medicine contains 12 mg benzoate salt (E211) in each 5 ml dose.

3. How to take VFEND
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Your doctor will determine your dose depending on your weight and the type of infection you have.

The recommended dose for adults (including elderly patients) is as follows:

<table>
<thead>
<tr>
<th>Oral suspension</th>
<th>Patients 40 kg and above</th>
<th>Patients less than 40 kg</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose for the first 24 hours</strong> (Loading Dose)</td>
<td>400 mg (10 ml) every 12 hours for the first 24 hours</td>
<td>200 mg (5 ml) every 12 hours for the first 24 hours</td>
</tr>
<tr>
<td><strong>Dose after the first 24 hours</strong> (Maintenance Dose)</td>
<td>200 mg (5 ml) twice a day</td>
<td>100 mg (2.5 ml) twice a day</td>
</tr>
</tbody>
</table>

Depending on your response to treatment, your doctor may increase the daily dose to 300 mg twice a day.

The doctor may decide to decrease the dose if you have mild to moderate cirrhosis.

Use in children and adolescents
The recommended dose for children and teenagers is as follows:

<table>
<thead>
<tr>
<th>Oral suspension</th>
<th>Patients 40 kg and above</th>
<th>Patients less than 40 kg</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose for the first 24 hours</strong> (Loading Dose)</td>
<td>Your treatment will be started as an infusion</td>
<td>400 mg every 12 hours for the first 24 hours</td>
</tr>
</tbody>
</table>
Dose after the first 24 hours
(Maintenance Dose)

<table>
<thead>
<tr>
<th>9 mg/kg twice a day</th>
<th>200 mg twice a day</th>
</tr>
</thead>
<tbody>
<tr>
<td>(a maximum dose of 350 mg twice daily)</td>
<td></td>
</tr>
</tbody>
</table>

Depending on your response to treatment, your doctor may increase or decrease the daily dose.

Take your suspension at least one hour before, or two hours after a meal.

If you or your child are taking VFEND for prevention of fungal infections, your doctor may stop giving VFEND if you or your child develop treatment related side effects.

VFEND suspension should not be mixed with any other medicine. The suspension should not be further diluted with water or any other liquids.

Instructions to constitute the suspension:
It is recommended that your pharmacist constitutes VFEND suspension before giving it to you. VFEND suspension is constituted if it is in a liquid form. If it appears to be a dry powder you should constitute the oral suspension by following the instructions below.

1. Tap the bottle to release the powder.
2. Remove the cap.
3. Add 2 measuring cups (measure cup included in the carton) of water (total of 46 ml) to the bottle. Fill the measuring cup to the top of the marked line then pour the water into the bottle. You should always add a total of 46 ml of water irrespective of the dose you are taking.
4. Replace the cap and shake the bottle vigorously for about 1 minute. Following constitution, the total volume of the suspension must be 75 ml.
5. Remove the cap. Press the bottle adaptor into the neck of the bottle (as shown on figure below). The adaptor is provided so that you can fill the oral syringe with medicine from the bottle. Replace the cap on the bottle.
6. Write the date of expiry of the constituted suspension on the bottle label (the shelf-life of the constituted suspension is 14 days). Any unused suspension should be discarded after this date.

Instructions for use:
Your pharmacist should advise you how to measure the medicine using the multi-dosing oral syringe provided in the pack. Please see instructions below before using VFEND suspension.
1. Shake the closed bottle of constituted suspension for approximately 10 seconds before use. Remove the cap.

2. While the bottle is upright, on a flat surface, insert the tip of the oral syringe into the adaptor.

3. Turn the bottle upside down while holding the oral syringe in place. Slowly pull back the plunger of the oral syringe to the graduation mark that marks the dose for you. To measure the dose accurately, the top edge of the black ring should be lined up with the graduated mark on the oral syringe.

4. If large bubbles can be seen, slowly push the plunger back into the syringe. This will force the medicine back into the bottle. Repeat step 3 again.

5. Turn the bottle back upright with the oral syringe still in place. Remove the oral syringe from the bottle.

6. Put the tip of the oral syringe into the mouth. Point the tip of the oral syringe towards the inside of the cheek. SLOWLY push down the plunger of the oral syringe. Do not squirt the medicine out quickly. If the medicine is to be given to a child, make sure the child is sitting, or is held, upright before giving the medicine.

7. Replace the cap on the bottle, leaving the bottle adaptor in place. Wash the oral syringe as instructed below.

**Cleaning and storing the syringe:**

1. The syringe should be washed after each dose. Pull the plunger out of the syringe and wash both parts in warm soapy water. Then rinse with water.

2. Dry the two parts. Push the plunger back in to the syringe. Keep it in a clean safe place with the medicine.

**If you take more VFEND than you should**

If you take more suspension than prescribed (or if someone else takes your suspension) you must seek medical advice or go to the nearest hospital casualty department immediately. Take your bottle of VFEND suspension with you. You may experience abnormal intolerance to light as a result of taking more VFEND than you should.

**If you forget to take VFEND**

It is important to take your VFEND suspension regularly at the same time each day. If you forget to take one dose, take your next dose when it is due. Do not take a double dose to make up for the forgotten dose.

**If you stop taking VFEND**

It has been shown that taking all doses at the appropriate times may greatly increase the effectiveness of your medicine. Therefore unless your doctor instructs you to stop treatment, it is important to keep taking VFEND correctly, as described above.

Continue taking VFEND until your doctor tells you to stop. Do not stop treatment early because your infection may not be cured. Patients with a weakened immune system or those with difficult infections may require long-term treatment to prevent the infection from returning.
When VFEND treatment is stopped by your doctor you should not experience any effects.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If any side effects occur, most are likely to be minor and temporary. However, some may be serious and need medical attention.

**Serious side effects – Stop taking VFEND and see a doctor immediately**

- Rash
- Jaundice; Changes in blood tests of liver function
- Pancreatitis

**Other side effects**

Very common: may affect more than 1 in 10 people

- Visual impairment (change in vision including blurred vision, visual colour alterations, abnormal intolerance to visual perception of light, colour blindness, eye disorder, halo vision, night blindness, swinging vision, seeing sparks, visual aura, visual acuity reduced, visual brightness, loss of part of the usual field of vision, spots before the eyes)
- Fever
- Rash
- Nausea, vomiting, diarrhoea
- Headache
- Swelling of the extremities
- Stomach pains
- Breathing difficulties
- Elevated liver enzymes

Common: may affect up to 1 in 10 people

- Inflammation of the sinuses, inflammation of the gums, chills, weakness
- Low numbers of some types, including severe, of red (sometimes immune-related) and/or white blood cells (sometimes with fever), low numbers of cells called platelets that help the blood to clot
- Low blood sugar, low blood potassium, low sodium in the blood
- Anxiety, depression, confusion, agitation, inability to sleep, hallucinations
- Seizures, tremors or uncontrolled muscle movements, tingling or abnormal skin sensations, increase in muscle tone, sleepiness, dizziness
- Bleeding in the eye
- Heart rhythm problems including very fast heartbeat, very slow heartbeat, fainting
- Low blood pressure, inflammation of a vein (which may be associated with the formation of a blood clot)
- Acute breathing difficulty, chest pain, swelling of the face (mouth, lips and around eyes), fluid accumulation in the lungs
- Constipation, indigestion, inflammation of the lips
- Jaundice, inflammation of the liver and liver injury
- Skin rashes which may lead to severe blistering and peeling of the skin characterized by a flat,
red area on the skin that is covered with small confluent bumps, redness of the skin
- Itchiness
- Hair loss
- Back pain
- Kidney failure, blood in the urine, changes in kidney function tests

Uncommon: may affect up to 1 in 100 people

- Flu-like symptoms, irritation and inflammation of the gastrointestinal tract, inflammation of the gastrointestinal tract causing antibiotic associated diarrhoea, inflammation of the lymphatic vessels
- Inflammation of the thin tissue that lines the inner wall of the abdomen and covers the abdominal organ
- Enlarged lymph glands (sometimes painful), failure of blood marrow, increased eosinophil
- Depressed function of the adrenal gland, underactive thyroid gland
- Abnormal brain function, Parkinson-like symptoms, nerve injury resulting in numbness, pain, tingling or burning in the hands or feet
- Problems with balance or coordination
- Swelling of the brain
- Double vision, serious conditions of the eye including: pain and inflammation of the eyes and eyelids, abnormal eye movement, damage to the optic nerve resulting in vision impairment, optic disc swelling
- Decreased sensitivity to touch
- Abnormal sense of taste
- Hearing difficulties, ringing in the ears, vertigo
- Inflammation of certain internal organs- pancreas and duodenum, swelling and inflammation of the tongue
- Enlarged liver, liver failure, gallbladder disease, gallstones
- Joint inflammation, inflammation of the veins under the skin (which may be associated with the formation of a blood clot)
- Inflammation of the kidney, proteins in the urine, damage to the kidney
- Very fast heart rate or skipped heartbeats, sometimes with erratic electrical impulses
- Abnormal electrocardiogram (ECG)
- Blood cholesterol increased, blood urea increased
- Allergic skin reactions (sometimes severe), including life-threatening skin condition that causes painful blisters and sores of the skin and mucous membranes, especially in the mouth, inflammation of the skin, hives, sunburn or severe skin reaction following exposure to light or sun, skin redness and irritation, red or purple discoloration of the skin which may be caused by low platelet count, eczema
- Infusion site reaction
- Allergic reaction or exaggerated immune response

Rare: may affect up to 1 in 1000 people

- Overactive thyroid gland
- Deterioration of brain function that is a serious complication of liver disease
- Loss of most fibres in the optic nerve, clouding of the cornea, involuntary movement of the eye
- Bullous photosensitivity
- A disorder in which the body’s immune system attacks part of the peripheral nervous system
- Heart rhythm or conduction problems (sometimes life threatening)
- Life threatening allergic reaction
- Disorder of blood clotting system
- Allergic skin reactions (sometimes severe), including rapid swelling (oedema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues, itchy or sore patches of thick, red skin
with silvery scales of skin, irritation of the skin and mucous membranes, life-threatening skin condition that causes large portions of the epidermis, the skin's outermost layer, to detach from the layers of skin below
- Small dry scaly skin patches, sometimes thick with spikes or ‘horns’

Side effects with frequency not known:
- Freckles and pigmented spots

Other significant side effects whose frequency is not known, but should be reported to your doctor immediately:
- Skin cancer
- Inflammation of the tissue surrounding the bone
- Red, scaly patches or ring-shaped skin lesions that may be a symptom of an autoimmune disease called cutaneous lupus erythematosus

As VFEND has been known to affect the liver and the kidney, your doctor should monitor the function of your liver and kidney by doing blood tests. Please advise your doctor if you have any stomach pains or if your stools have a different consistency.

There have been reports of skin cancer in patients treated with VFEND for long periods of time.

Sunburn or severe skin reaction following exposure to light or sun was experienced more frequently in children. If you or your child develops skin disorders, your doctor may refer you to a dermatologist, who after consultation may decide that it is important for you or your child to be seen on a regular basis. Elevated liver enzymes were also observed more frequently in children.

If any of these side effects persist or are troublesome, please tell your doctor.

**Reporting of side effects**
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

**5. How to store VFEND**
Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.

Powder for oral suspension: store at 2°C - 8°C (in a refrigerator) before constitution.
For the constituted suspension:
Do not store above 30°C.
Do not refrigerate or freeze.
Store in the original container
Keep the container tightly closed.
Any remaining suspension should be discarded 14 days after constitution.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer required. These measures will help protect the environment.
6. Contents of the pack and other information

What VFEND contains:
- The active substance is voriconazole. Each bottle contains 45 g of powder providing 70 ml of suspension when constituted with water as recommended. One ml of the constituted suspension contains 40 mg voriconazole. (See section 3 ‘How to take VFEND’).
- The other ingredients are sucrose; silica colloidal; titanium dioxide; xanthan gum; sodium citrate; sodium benzoate; citric acid; natural orange flavour (see section 2, VFEND 40 mg/ml powder for oral suspension contains sucrose, benzoate salt (sodium benzoate) and sodium).

What VFEND looks like and contents of the pack
VFEND is supplied as a white to off-white powder for oral suspension providing a white to off-white, orange flavoured suspension when constituted with water.

Marketing Authorisation Holder
Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium

Manufacturer
Fareva Amboise, Zone Industrielle, 29 Route des Industries, 37530 Pocé-sur-Cisse, France.

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

United Kingdom
Pfizer Limited
Tel: +44 (0)1304 616161

This leaflet was last approved in 09/2020.

Ref: VF 42_0

Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu